Bruning P F, Pit M J, de Jong-Bakker M, van den Ende A, Hart A, van Enk A
The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Amsterdam.
Br J Cancer. 1990 Feb;61(2):308-10. doi: 10.1038/bjc.1990.58.
Lumbar bone mineral density (BMD) determination by dual photon absorptiometry was used to study the influence of adjuvant chemotherapy for premenopausal breast cancer on the risk of premature osteoporosis. Six cycles of combination chemotherapy caused ovarian failure in 31 of 44 (71%) women, amenorrhoea mostly already beginning during treatment. In contrast, only seven of 44 (16%) women, who were pair-matched for age and year of breast cancer surgery and had not been treated with chemotherapy, were post-menopausal at the time of measurement. The mean interval after breast surgery was 3.5 years. The significantly decreased BMD in the treated group (1.17 compared to 1.29 g cm-2) could only be explained by the high incidence of menopause in these women, which on average occurred 10 years prematurely. Extrapolation of these findings suggests that adjuvant chemotherapy may precipitate osteoporotic fractures by some 10 years in a considerable proportion of women cured of premenopausal breast cancer.
采用双能光子吸收法测定腰椎骨密度，以研究绝经前乳腺癌辅助化疗对过早发生骨质疏松风险的影响。44名女性中，31名（71%）在接受六个周期的联合化疗后出现卵巢功能衰竭，闭经大多在治疗期间就已开始。相比之下，44名年龄和乳腺癌手术年份匹配且未接受化疗的女性中，只有7名（16%）在测量时已绝经。乳腺癌手术后的平均间隔时间为3.5年。治疗组骨密度显著降低（1.17 g/cm²，而对照组为1.29 g/cm²），这只能解释为这些女性绝经发生率高，平均提前了10年。根据这些研究结果推断，辅助化疗可能会使相当一部分治愈的绝经前乳腺癌女性的骨质疏松性骨折提前约10年发生。
